Recent News

By Category: Countermeasures

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule

BUSINESS WIRE (ROCKVILLE) — Emergent BioSolutions Inc. announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest single-week regulatory release of product Read More »

June 2, 2011
| Filed under North America, Biotechnology, and Countermeasures
Share

Army Awards PPD Contract to Support Biodefense, Vaccine Development Programs

GOVCONWIRE — The U.S. Army has awarded PPD, Inc. (NASDAQ: PPDI) the U.S. Army Medical Research Acquisition Activity: Regulatory Affairs & Compliance Support contract to provide global regulatory and biostatistical services for several Army clinical development programs. It is a multiyear, indefinite delivery, indefinite quantity contract with a ceiling value of $45.5 million over a Read More »

June 2, 2011
| Filed under North America, Countermeasures, and Policy & Initiatives
Share

Industry, Academia Race to Create Drugs Against Biological Warfare

NATIONAL DEFENSE MAGAZINE — Experts tend to arrange biological threats in tiers. And anthrax may very well have an entire shelf to itself. After all, it was a series of deadly letters containing anthrax sent through the mail just weeks after 9/11 that spawned the biodefense industry as it exists today. On the heels of Read More »

June 1, 2011
| Filed under North America, Biological Weapons, Bioterrorism, and Countermeasures
Share

U.S. Plans New Order of Anthrax Vaccine

The United States is preparing a deal with Maryland-based Emergent BioSolutions for the purchase over five years of 44.75 million additional anthrax vaccine doses, the firm announced on Thursday (see GSN, May 3). The company expects between July and September to conclude the new agreement, which would provide the additional doses of BioThrax for the Read More »

May 31, 2011
| Filed under Biotechnology and Countermeasures
Share

FDA clears first ever diagnostic test for Q fever

The FDA has cleared the first nucleic acid amplification test to diagnose the early stages of Q fever infections in military personnel serving overseas, according to an FDA press release. “It’s important that the FDA protect our troops from biothreats using innovative diagnostics,” Jeffrey Shuren, MD, director of the FDA’s Center for Devices and Radiological Read More »